Podcasts about lecanemab

Send us a textWe trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab's Alzheimer's trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.

A new Health Canada-approved drug called lecanemab has been shown to slow early-stage Alzheimer's disease. Neurologist Dr. Sharon Cohen, who participated in phase three trials for the drug, explains why lecanemab is such a big deal.For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.

Send us a textLast week, Health Canada gave the green light to a long-awaited drug that slows the progression of early-stage Alzheimer's disease.Lecanemab is the first approved medication that targets the buildup of amyloid plaque in the brain, believed to be an underlying cause of Alzheimer's.For patients and their loved ones across the country, the approval could not have come fast enough. According to the Alzheimer's Society of Canada, there are close to 800,000 people in the country living with some form of dementia right now — a number that's expected to hit 1 million by 2030.Dr. Howard Chertkow is a senior scientist at the Baycrest Academy for Research and Education, and one of Canada's leading experts on dementia. He joins us on tonight's Closer Look to discuss the new drug — but also why he believes this could be a “turnaround decade” in the treatment, prevention and early diagnosis of Alzheimer's disease and other types of dementia.Hosted by Village Media's Michael Friscolanti and Scott Sexsmith, and produced by Derek Turner, Closer Look is a new daily podcast that goes way beyond the headlines with insightful, in-depth conversations featuring our reporters and editors, leading experts, key stakeholders and big newsmakers.Fresh episodes drop every Monday to Friday at 7 p.m. right in your local news feed — and on the show's dedicated website: closerlookpodcast.ca. Of course, you can also find us wherever you get your favourite podcasts.Want to be the first to know when a new episode lands? Sign up for our free nightly newsletter, which delivers the latest Closer Look straight to your email inbox. You can also subscribe to our YouTube channel or follow us on X, Instagram, Facebook and TikTok.Have something to say? Please reach out. Our email address is closerlook@villagemedia.ca.

Caring for someone living with dementia can be both deeply meaningful and incredibly challenging. Finding effective ways to connect, communicate and provide support often requires shifting how we see and respond to changes in the brain. In honor of National Family Caregivers Month, renowned dementia care specialist Teepa Snow joins the podcast to share her insights on improving life with dementia through empathy and understanding. As the founder of Positive Approach to Care (PAC), Teepa has developed the Snow Approach, a set of practical and compassionate techniques designed to empower care partners. She discusses the philosophy behind her methods, the importance of recognizing retained abilities and strategies that can make daily interactions more positive and meaningful for both care partners and those living with dementia. Guest: Teepa Snow, MS, OTR/L, FAOTA, dementia care specialist, educator, owner, trainer, Positive Approach LLC, co-Founder & chair, Snow Approach Foundation Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on November 5, 2025. Watch the video interview with Teepa Snow here. Find videos, resources and more on Teepa Snow's website. Interested in hearing more from Teepa? Attend Dementia Friendly America's (DFA) Dementia Friendsgiving on Tuesday, November 18, 2025, to hear her keynote talk on supporting people with dementia in dignified and respectful ways. Learn more about lecanemab and the eligibility requirements from our past episode, “Looking at Lecanemab's Eligibility Guidelines and Prescription Process,” on our website. Learn more about grief and dementia from our past episode, “A Guide to Grief: Strategies for Navigating Loss and Dementia,” on our website. Learn more about the National Council of Dementia Minds on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

Lecanemab is a new drug that's being made available in Canada to slow the early stage of Alzheimer's disease. We speak to Linda McMaster, who is on the waitlist to receive it. And Drs Sandra Cohen and Samir Sinha about the efficacy, cost and reality of how this new drug fits in with the wider Alzheimer's care environment in Canada today.

In 2023, I was determined to have early Alzheimer's and was confirmed in early 2024 with a spinal tap. I began the newest treatment called Lecanemab and after 36 of those treatments and a recent PET scan and other tests, my doctor told me just an hour or so ago that my Alzheimer's is in remission. In fact, he said we don't even have a word for it, so we are using that word remission. Thanks be to God. #god #healing #jesus #alzheimer #remission #lecanemab Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Es gibt ein neues Medikament gegen Alzheimer. Die Neurologin Elisabeth Stögmann über das Wirkprinzip, die Risiken und die Erfolgsaussichten von neuen Therapien. Ein Podcast vom Pragmaticus.Das Thema:Lecanemab heißt der neue Wirkstoff, der erstmals gegen die Ursachen der Alzheimer-Erkrankung zu Felde zieht: die Amyloid-beta-Plaques, die sich im Gehirn von Alzheimer-Kranken anlagern und die Denkfähigkeit zerstören. Anfang September hat der erste Patient in Österreich diese Substanz erhalten. „Es ist ein Meilenstein“, ist Neurologin Elisabeth Stögmann, Präsidentin der Alzheimer-Gesellschaft Österreich, überzeugt.In diesem Podcast beschreibt sie, wie dieses neue Medikament wirkt, für wen es in Frage kommt und mit welcher Wirksamkeit gerechnet werden kann. Und sie gibt auch Auskunft darüber, welche anderen Substanzen noch in der Pipeline gegen Alzheimer sind. Ein Gespräch über Status Quo, Perspektive und Prävention einer Erkrankung, von der 150.000 Menschen in Österreich betroffen sind.Unser Gast in dieser Folge: Elisabeth Stögmann ist Neurologin, ihr Spezialgebiet ist Alzheimer. Sie leitet die Gedächtnisambulanz am Wiener AKH und erforscht die Genetik, Entstehung und biomolekularen Eigenschaften der Erkrankung. Dazu ist sie an vielen internationalen Forschungsprojekten beteiligt, darunter die große EU-Horizont 2020-Studie und klinische Studien zu Medikamenten. Sie hat bei über 100 begutachteten (peer reviewed) Publikationen mitgewirkt. Stögmann ist derzeit auch Präsidentin der Österreichischen Alzheimer-Gesellschaft, Referentin auf internationalen Konferenzen und arbeitet mit Institutionen in ganz Europa zusammen.Dies ist ein Podcast von Der Pragmaticus. Sie finden uns auch auf Instagram, Facebook, LinkedIn und X (Twitter).  

Selten hat die Einführung neuer Arzneimittel so viel mediale Aufmerksamkeit erzeugt wie die jüngste Zulassung von Lecanemab (Leqembi) und Donanemab (Kisunla). Am Donnerstagmittag, 2. Oktober, haben wir beim 59. DEGAM-Kongress in Hannover darüber gesprochen – und live mit Publikum diese Episode des EvidenzUpdate-Podcasts aufgezeichnet. Großer Dank an unseren Special Guest Thomas Duning, Chefarzt der Klinik für Neurologie am Klinikum Bremen-Ost. Und großer Dank an alle Teilnehmenden für das angeregte Gespräch!

Über 1,8 Millionen Menschen leben in Deutschland mit einer Demenz, davon etwa zwei Drittel mit Alzheimer. Seit Anfang September gibt es mit dem Medikament Lecanemab eine neue Therapie, die den Krankheitsverlauf im Frühstadium verlangsamen kann. Wie läuft sie ab, was sind die Vorteile? Und welche Nebenwirkungen gibt es? Martin Gramlich im Gespräch mit Prof. Jonas Hosp, Universitätsklinikum Freiburg.

In dieser Sendung geht es um die neuen Medikamente gegen Alzheimer – die Wirkstoffe heißen Lecanemab und Donanemab. Diese Medikamente greifen zum ersten Mal in den Pathomechanismus der Alzheimererkrankung ein, lindern also nicht nur Symptome, sondern bekämpfen die Ursachen der Alzheimererkrankung. Mit Saskia Weiß, der Geschäftsführerin der Deutschen Alzheimer Gesellschaft und Prof. Dr. René Thyrian vom Deutschen Zentrum für Neurodegenerative Erkrankungen (DZNE), Greifswald und Vorstandsmitglied der Deutschen Alzheimer Gesellschaft, sprechen wir über Wirkungsweise, Möglichkeiten und Grenzen der Medikamente und darüber, welche Fragen im Bereich Diagnostik und in der Versorgung diese aufwerfen. Wir ordnen ein, was wir im Moment schon an bekannten Medikamenten, aber auch an anderen, sogenannten nicht-medikamentösen Therapien haben und was jede und jeder tun kann, um einer Demenzerkrankung zu begegnen. Interviewpartner:innen: Saskia Weiß, Geschäftsführerin der Deutschen Alzheimer Gesellschaft Prof. Dr. Jochen René Thyrian, Dipl.-Psych., Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Greifswald

Alzheimer's Disease Treatment With Lecanemab - my personal experience Lecanemab and how that has gone so well #alzheimer #dementia #lecanemab #jesus Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this podcast accompanying the August issue of DTB (https://dtb.bmj.com/content/63/8), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) (https://dtb.bmj.com/content/63/8/114) which looks at the role of AI in publishing. They talk about a DTB Forum article (https://dtb.bmj.com/content/63/8/115) that explores some of the practical problems of implementing drug safety alerts.  A DTB Select article (https://dtb.bmj.com/content/63/8/117) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article (https://dtb.bmj.com/content/63/8/118) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease.   Link BMJ policy on AI use: https://www.bmj.com/content/ai-use 

Le Pr David Wallon, neurologue et chercheur, dirige le Centre Mémoire de Ressource et de Recherche au CHU de Rouen et préside la Fédération des Centres Mémoire. Ses travaux de recherche portent essentiellement sur la forme précoce de la MA et plus particulièrement sur les causes génétiques de ces formes précoces. Aujourd'hui, David Wallon nous parle du nouveau traitement porteur d'espoir, le lecanemab. Cette immunothérapie agit pour développer des anticorps afin de nettoyer le peptide amyloïde du cerveau des patients.  Au cours de cet entretien, le Pr David Wallon aborde tous les aspects du traitement :  Efficacité Limites Mode d'administration et contrôles  Effets indésirables  Populations autorisées à recevoir le traitement et populations exclues Retour d'expérience sur son utilisation aux Etats-Unis et Japon Autorisation européenne et étapes de validation en France … Dans cet épisode passionnant de Podc'Alz, le Pr David Wallon nous donne également sa vision de l'avenir de la recherche sur Alzheimer. 

Investigative journalist Charles Piller explains the remarkable story of fraud he has uncovered in Alzheimer's Disease research, which he discusses in a new book: Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's. Charles argues the result of this is that Alzheimer's research and treatment has been set by years - if not decades. He goes on to discusse the trial data on which several Alzheimer's drugs, including Aducanumab, Lecanemab and Donanemab, were approved. Charles says the data is unconvincing and  the side effects – including brain swelling and bleeding -  concerning. Doctored: Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's by Charles Piller is published by Icon Books. Charles Piller is an investigative journalist who works for the journal Science. His work has also been published in a number of other publications including The New York Times and the Los Angeles Times. Charles has won a number of journalism awards for his work and is also the author of the books Gene Wars and The Fail-Safe Society. The host of the podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director.  You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com If you would like to support this podcast you can do so via Patreon at https://www.patreon.com/WhatYourGPDoesntTellYou or via PayPal at https://www.whatyourgpdoesnttellyou.com/support/ What Your GP Doesn't Tell You has been selected by Feedspot as one of the top 15 UK Medical Podcasts https://blog.feedspot.com/uk_medical_podcasts/

Heute spreche ich mit Prof. Andrea Pfeifer, Gründerin und CEO des Schweizer Biotechunternehmens AC Immune, über einen der spannendsten Fortschritte im Kampf gegen Alzheimer: die aktive Immuntherapie. Jahrzehntelang galten neurodegenerative Erkrankungen wie Alzheimer und Parkinson als unbezwingbar – doch nun zeichnet sich ein Wandel ab. Wir sprechen über fehlgefaltete Proteine, intelligente Antikörper, die gezielt ins Gehirn vordringen, und darüber, warum Früherkennung entscheidend ist. Ein Gespräch voller Hoffnung, Tiefe und wissenschaftlicher Präzision – für alle, die sich für Longevity, Prävention und neue Perspektiven in der Medizin interessieren.  In dieser Folge sprechen wir u.a. über folgende Themen:  Warum ist eine frühe Diagnose und Behandlung von Alzheimer entscheidend für den Therapieerfolg? Welche Rolle spielt das Immunsystem bei der Erkennung und Beseitigung pathologischer Proteine im Gehirn? Wie unterscheiden sich aktive Immuntherapien von den aktuell zugelassenen monoklonalen Antikörpern wie Donanemab oder Lecanemab? Inwiefern könnten neue Therapien dazu beitragen, Alzheimer nicht nur zu behandeln, sondern möglicherweise zu verhindern? Warum betrifft Alzheimer besonders viele Frauen, und wie reagiert die Forschung auf diese Erkenntnis? Was sind Liposomen und wie aktivieren sie das Immunsystem zur Bildung gezielter Antikörper gegen Alzheimer? Welche Rolle spielen Mikrogliazellen im Prozess der sogenannten Phagozytose bei der Plaque-Beseitigung im Gehirn? Wie weit ist AC Immune in der Entwicklung wirksamer Alzheimer- und Parkinson-Therapien – und was bedeutet Phase 2 der klinischen Studien? Warum vergleicht Prof. Pfeiffer Antikörper mit intelligenten „Suchdrohnen“ im Kampf gegen Alzheimer? Wie kann es gelingen, das Fortschreiten der Tau-Kaskade zu stoppen – und warum ist das der Schlüssel zur wirksamen Alzheimer-Prävention? Welche Learnings aus 20 Jahren Alzheimer-Forschung fließen heute in die Entwicklung innovativer Immuntherapien ein?   Weitere Informationen zu Prof. Andrea Pfeiffer findest du hier:  https://www.acimmune.com/  Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g   Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin.  STY-192  

Elizabeth Kensinger, PhD and Andrew Budson, MD explain how healthy lifestyle habits, memory offloading strategies, and turning facts into stories can support cognitive aging. They stress that enriching and novel activities are more effective for brain health than most apps. Dr. Budson supports the theory that beta amyloid defends against brain infections, linking it to viral triggers of Alzheimer's. He also highlights new drugs like lecanemab and donanemab that may slow early Alzheimer's progression and potentially prevent its onset.

I have Alzheimer's - I was diagnosed by spinal tap and I am undergoing treatment with the drug Lecanemab by infusion every 2 weeks. By God's grace, I am finding ways to embrace my condition in a way that makes me more and not less - that my life still has meaning and purpose but now even more so. I have done quite a few of these and my goal is to bring positive attention to mental health issues and to be an encourager for others. Erosion Of The Mind (Mental Health Update) #alzheimer's #alzheimers #dementia #mentalhealth #mental #health #mentalerosion #update #hollismcgehee #aimingforjesus

Kohlenbach, Lukas www.deutschlandfunk.de, Forschung aktuell

Anti-amyloid therapies provide the first FDA-approved option to alter AD pathology, but an understanding of overall utility and value to patients remains in its infancy. In this episode, Teshamae Monteith, MD, FAAN, speaks with David S. Geldmacher, MD, FACP, FANA, author of the article “Treatment of Alzheimer Disease” in the Continuum® December 2024 Dementia issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Geldmacher is a professor and Warren Family Endowed Chair in Neurology and the director of the Division of Cognitive and Behavioral Neurology, Department of Neurology, Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham in Birmingham, Alabama. Additional Resources Read the article: Treatment of Alzheimer Disease Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today, I'm interviewing Dr David Geldmacher about his article on treatment of Alzheimer's disease, which appears in the December 2024 Continuum issue on dementia. Welcome to our podcast, Dr Geldmacher. How are you?  Dr Geldmacher: I'm very well, thank you. It's a pleasure to be here.  Dr Monteith: Yeah. So, why don't you introduce yourself to our audience? Dr Geldmacher: Sure. I'm David Geldmacher. I'm a professor of neurology at the University of Alabama in Birmingham and I lead the division of Cognitive and Behavioral Neurology.  Dr Monteith: So, I'm really excited about this, to personally learn, and I know that or neurology community is also really excited about this interview. So, why don't we start off with your main objective.  Dr Geldmacher: So, my main goal in the article was to review the FDA-approved pharmacologic treatments for dementia. There's lots of ways of thinking about treatment of dementia; psychosocial, caregiver support, and so forth. But I really wanted to focus on the issues of drug treatment because that's what has been our backbone for a long time and now has recently expanded.  Dr Monteith: Why don't we talk a little bit about, first of all, the boom in the field? What's that been like?  Dr Geldmacher: So, the big change in the field is over the last several years, we've had treatments become available that actually attack the underlying Alzheimer pathology, and that's new and different. For decades, we've been able to treat the symptoms of the disease, but this is the first time we've really been able to get to the root of the pathology and look toward removing amyloid plaques from the brain.  Dr Monteith: Let's step back a little bit and talk about the framework of diagnosis and how that leads into the therapeutic potential. I know you're going to dive into some of the biologics, but we should probably talk about the kind of holistic approach to considering the diagnosis. Dr Geldmacher: Sure. So, you know, when someone comes to the clinic with memory complaints, our question we have to ask is, is this neurologic origin, a structural origin like Alzheimer's disease or vascular dementia? Are there complicating factors, the software issues of mood disorders and sleep disorders and pain that can all magnify those symptoms? The clinical reasoning is a critical part of that, but in Alzheimer's disease, typically the problems revolve around difficulty forming new memories of events and activities, the episodic memory. And then it's often accompanied by changes in word finding and semantic knowledge. And those are the things that we look for in the clinic to really point toward an AD diagnosis. And then we support it with exclusion of other causes through blood work and identification of patterns of brain atrophy on MRI. And then most recently in the last couple of years, we've been able to add to that molecular imaging for amyloid with PET scans as well as, most recently, blood-based biomarkers for Alzheimer's pathology. So, it's really been a revolution in the diagnosis over these last several years.  Dr Monteith: And when approaching patients or populations of individuals, there seems to be a real full spectrum with looking at the societal burden, the biological impact, of course, risk factors of primary prevention, and now this whole area of brain health and secondary prevention. How do you kind of tie all of this together when talking to patients and family members?  Dr Geldmacher: Sure. So, the approaches for brain health apply to everyone. In basically every clinic visited, our brain aging and memory clinic, we reviewed lifestyle approaches to brain health like regular physical exercise, healthy diet, cognitive and social stimulation. And those are fundamental to the approach to everyone, whether they have cognitive impairments that are measurable or not. These are all things that are good for our brain health. And then, you know, focusing on the vascular risk factors in particular and working with the patient and their primary care team to ensure that lipids and blood sugar and blood pressure are all in good healthy ranges and being appropriately treated.  Dr Monteith: You know, there's this kind of whole considerations of clinically meaningful endpoints and clinical trials, and even when we're talking to our patients. What would you say the field has kind of identified has the best endpoints in helping patients? Would you call it impaired daily function? Is that like the best hard endpoint? Obviously, there are other things such as caregiver burden, but you know, how do you approach assessing patients? Dr Geldmacher: Defining the endpoints is very difficult. Typically, if we talk to patients and their families, they would like to have better memory or improve memory. How that applies in everyday life actually is daily function. And so, we focus very much on daily function. And when I talk about our therapies, whether they're symptomatic therapies or the new disease-modifying therapies, I really talk about maintenance of function and delays and decline or slowing of decline, helping to foster the person's independence in the activities that they have and be able to sustain that over the longer term.  Dr Monteith: And when thinking about diagnosis- and we're going to get into treatments, but when thinking about the diagnosis, and of course, it's full-spectrum from mild cognitive impairment to moderate and severe forms of dementia, but who should have CSF testing and PET imaging? Obviously, these are invasive, somewhat invasive and expensive tests. Should all people that walk in the door that have memory complaints? How do you stratify who should have tests? Dr Geldmacher: I think about this in a big funnel, basically, and the starting point of the funnel, of course, is the person with memory complaints. Then there's that neurologic reasoning. Are these memory complaints consistent with what we expect from the anatomy of Alzheimer's disease, with atrophy in in the hippocampus and temporal lobe? Do they have episodic memory loss or not? That first step is really trying to characterize, do the clinical patterns act like those of Alzheimer's disease or not? And then we follow the Academy of Neurology guidelines, looking for reversible sources of cognitive decline, things like B12 deficiency and depression, sleep disorders and the like, and try to exclude those. We start with structural imaging with everyone, and MRI, typically, that will help us understand vascular burden and patterns of atrophy, looking for things like mesial temporal atrophy or precuneus atrophy that are characteristic of Alzheimer's disease. If those things are all pointing in the direction of AD as opposed to something else, then typically before moving on to CSF or PET scan, we will use blood-based biomarkers, which are one of the big changes in the field in the last year or so, and there are now multiple panels of these available. The downside is they are typically not covered by insurance. On the other hand, they can really help us identify who is likely to have a positive PET scan or positive findings on CSF. We start to provide that counseling and information to the patient before they get to those more definitive tests. We can push people in the other direction. We can say, your blood-based biomarkers are negative or do not indicate AD as the most likely source of your condition now, so let's treat other things. Let's see what else we can focus on. The blood-based biomarkers are now, in our clinic at least, the critical choke point between the routine workout that we've always done on everyone and then the more advanced workup of proving amyloid pathology with CSF or a PET scan. Dr Monteith: How sensitive are those blood biomarkers and how early are they positive?  Dr Geldmacher: The sensitivity is generally pretty good, in the ninety plus percent range on average and it depends on which panel. And as you point out, when in the course of symptoms that they're done, we know that they become positive and presymptomatic or asymptomatic people. We're using these kinds of markers to screen people for prevention trials. So, I think when someone is symptomatic, they're a good indicator of the presence or absence of AD pathology. Now that doesn't mean the AD pathology is the sole cause of their symptoms. And so, we still need to think about those other things like sleep and mood and so forth. But they do point us in the in the direction of Alzheimer's change.  Dr Monteith: So why don't we talk about some of the more standard older treatments, and it's also important to leave with kind of some rational approach to when we start and what should we be counseling our patients on. So why don't we start with the older, you know, choline esterase inhibitors and then some of the MDA- I guess there's only one modulator, SEPTA modulator. Dr Geldmacher: So, I've been really fortunate in my career span, the time from the first of those symptomatic agents reaching the market in 1993 to seeing the disease modifying drugs enter the market now. I think most neurologists actually have entered practice after those clinical trials of the colon esterase inhibitors were published. So, one of my goals in this article was to review that primary data and what can we expect from those symptomatic drugs. We know that they are inconsistently effective in mild cognitive impairment, and the Academy of Neurology guidelines says there is not strong evidence to use them in mild cognitive impairment. But in mild AD and beyond, the cholinesterase inhibitors provide meaningful benefits. They delay decline, they can delay nursing home placement. They reduce overall costs of care. So, I think they provide real value. So, in the article I have reviewed what the data looked like on those. My approach is to start with oral Donepezil at five milligrams and increase it to ten in everyone who tolerates the five. If for whatever reason the oral Donepezil is not well tolerated, I'll switch to transdermal rivastigmine to help improve tolerability. There are very few head to head comparisons, but nothing suggests that one of the cholinesterase inhibitors is superior to the other for clinical outcomes, and there's no evidence to support conjoint use of more than one at a time. Should someone be showing decline then on typical cholinesterase inhibitor therapy - and people will, it's often delayed, but the decline will reemerge - then I will add the NMDA receptor, a modulator memantine and titrate that up to full dosing, either 10 mg twice a day for the conventional release or 22 mg extended release. And at that point we're sort of on maximal pharmacologic therapy for Alzheimer's disease. These agents can provide some benefit in other conditions, they're off-label except for Lewy body disease where rivastigmine is labeled. But they can provide benefit across different conditions. And there's some preliminary data, for instance, of acetylcholinesterase inhibitors being helpful in vascular cognitive impairment. So, I will use them, but I expect the greatest response when someone really does follow the patterns of Alzheimer's disease.  Dr Monteith: And you have a great chart, by the way, and nice figures looking at some of the meta-analyses on cognitive outcomes as well as functional outcomes. So, thank you for that.  Dr Geldmacher: In general, all of those tables favor treatment over placebo in the domains of cognition, daily function, neuropsychiatric symptoms. And it's that consistency of result that lets me know that we really are seeing a drug effect, that it's not a class effect with those, that we really are helping our patients. It's not like some studies are positive and some are negative. They are very consistently positive. Small magnitude, but consistently positive.  Dr Monteith: And I know we have a lot of patients coming in where, at least, their caregivers are complaining about agitation, and sleep is also a problem for others. And so how do you help that patient? I know you have a good algorithm that also you included in your article, but why don't you summarize how we should approach these symptoms? Dr Geldmacher: Sure. So, for nonpsychotic agitation, you know, just restlessness, wandering, pacing and so forth, my first choice is an off-label use of citalopram. And there is good clinical trials evidence to support that. if someone has psychotic agitation that is with delusions or hallucinations and so forth, I think we do need to move to the antipsychotic drugs. And the one drug that is now approved for treatment of agitation and Alzheimer's disease does fall into that antipsychotic category, along with its various black box warnings - and that's brexpiprazole. For many of our patients, getting coverage for that agent is difficult. It's not on many formularies. So, it is something I progress toward rather than start with. Similarly, for sleep, there is one approved agent for sleep, that's a dual orexin agonist. And it shows effectiveness, but can have some negative cognitive effects, and so I tend not to start with that either. My first choice when sleep is the primary issue for our patients with dementia is trazodone, and there are some small, limited studies for it's off-label used to enhance sleep. It's safe, inexpensive, often effective, and therefore it's my first choice. Dr Monteith: So, now let's get into the big conversations that everyone is having. Let's talk about the newer disease modifying anti amyloid therapies. Give us a summary dating back 2021 probably, although we can hold the preclinical work, but let's talk about what is available to our patients. Dr Geldmacher: Sure. And the development of anti-amyloid therapies goes all the way back to 1999. So, it's a pretty long course to get us to where we are today.  Dr Monteith: Yeah, that's why we limited that.  Dr Geldmacher: With that first approved agent with aducanumab in 2021, it received a limited or accelerated approval in FDA parlance. These agents, the aducanumab, lecanemab and donanemab, all approved, are known to remove amyloid pathology from the brain as measured by CSF and/or BIPET. They are amyloid lowering therapies, often called disease-modifying therapies. And across the agents there's some variable results. But if we look at the two with full approval, lecanemab and donanemab, they slow clinical progression by 25% to 35% on average. And that's measured by either cognitive measures or global measures or composite measures, but it's pretty consistent in that range of about one-third slowing. That makes it really difficult to discern in an individual patient, though, because there's so much variability in the progression of the disease already that it can be difficult to tell in one person that these drugs are working. They're also complex to use, so there's a qualification process that involves MRI to exclude things like a high tendency toward hemorrhage. It includes genetic testing for papal E4 status to help us understand the risk for complication, and then once-monthly or twice-monthly infusions with standardized schedule for MRI scanning. So, there's a lot that goes into managing these agents. And they are expensive, and we don't yet know their cost effectiveness. The cost effectiveness of the cholinesterase inhibitors was questioned when they first came out back in the 1990s, and it took five or ten years to really understand that they provided benefit to society and to individuals in those domains of quality of life and return on investment. And we're still learning about that with the disease modifying therapies.  Dr Monteith: So, two questions. One, the case that you presented was an individual having symptoms and kind of voiced their desire to be on these therapies. So, people are going to be asking, coming to clinic asking and then of course, they're going to be people that you select out. So, how do you make that decision to recommend this treatment for patients given the potential risk? Dr Geldmacher: We've got some really good guidance from appropriate use recommendation papers for aducanumab and lecanemab, and I'm expecting one from donanemab fairly soon. But the key is to identify individualized risks, and that involves knowing their APOE4 status, knowing their- whether they've had microhemorrhages in the brain previously, and then documenting that they really do have amyloid pathology with something like PET scan to establish those baselines. I talk to people about the burden of twice-monthly infusions or, now with donanemab, once-monthly infusions. And for instance, for someone who's got a working caregiver, getting to an infusion center twice a month can be a significant burden. And then if there are complications, frequent MRI scans and so forth. So, we talk about the burden of entering into this therapeutic pathway. The reality is that people who are qualified generally want it. I have relatively few folks who have said, no, these risks are more than I'm willing to accept. For decades my patients have said, anything you can do to slow this down, I'm willing to try. And now we're seeing that translated to reality with people willing to accept high-risk, high-cost treatments with the chance of slowing their individual progression.  Dr Monteith: And how do you select between the two treatments? Dr Geldmacher: So far that's been easy because donanemab's not readily available.  Dr Monteith: Outside of clinical trials, right?  Dr Geldmacher: Exactly. For prescription use, it's coming in - the first cases have now been infused - but it's not generally available. Nonetheless, what I will do for patients in this is look at the risk tables. So donanemab appears to have in general some higher rates of the Aria complications, amyloid-related imaging anomalies, and some people are going to be more risk tolerant of that for the payoff of potentially faster response. The donanemab trials restructured that. They did their first assessment of effectiveness. I had amyloid removal at six months and a significant proportion of people were eligible to discontinue treatment at six months because their amyloid was below treatable thresholds. So higher risk, perhaps faster action and fewer infusions for donanemab. Lecanemab we have more direct experience with, and between the two of them, the eighteen month outcomes are pretty much the same and indistinguishable. So are we in it for a quick hit, or are we in it for the long race? And different patients and different families will have differing opinions on where they want to accept that risk and burden and so forth. But so far, the data don't indicate a lot of difference in their longer-term outcomes. We still have plenty to learn.  Dr Monteith: And so, it sounds like, as you mentioned, we're looking at eighteen months out for kind of a hard outcome, and that there is a lot of variability in response rate. How are you tracking patients- you know about the imaging, so just in terms of clinical outcomes and efficacy?  Dr Geldmacher: Sure. So, for Medicare to reimburse on these treatments, people need to be enrolled in a registry program - and there are several of these, CMS runs one of their own. But the requirement for that is, every six months, to do cognitive and functional outcomes through the first two years. Cognitive outcomes are up to the clinician, but things like the mini mental state exam, the MoCA, are appropriate. In our own program, we use something we developed locally called the Alabama Brief Cognitive Screener. As for the cognitive outcomes and then for functional, we use an instrument called the General Activities of Daily Living Scale, but there are many other ADL scales that could be used as well. CMS does not mandate specific tests. Since the progression of the disease is variable to begin with, we don't really know how to interpret these results in reference to whether the drug is working, but I can tell a patient or a family member, your scores are stable, or, you have a decline of three points in this test. That's typical for this duration of illness. But there isn't a good way to know whether the drug is working in this person at this time, at least with our current levels of data.  Dr Monteith: So, I think we have to talk about health equity, and it sounds like Medicare is reimbursing for some of us. We look at different socioeconomic backgrounds, educational backgrounds, race, ethnicity. Not everyone is aware of these treatments. So, how do we get more patients to become aware of these treatments? And how do we get them to more people to help people? Dr Geldmacher: Yeah, I mean, that's- it's a major, major issue of inequity in our population. We've done some work at UAB looking at the flow of members of minority communities into memory clinics. So, we know that the overall population of, and I'll choose, for an example, blacks and African Americans, that they are represented a much higher rate in our overall UAB treatment population than they are in our memory clinic population. So, they're not even getting to us in the specialty clinic at the same rates as other segments of our population. We also know that blacks and African Americans in our population are not receiving PET scans as often as the overall treatment population. So yes, there are real, real problems with access. There are cultural issues behind this as well. And in many communities, a change in cognition, a loss of memory is an expected part of the aging process rather than recognized as a disease. So, people who come to us from minority communities are often further along in the course of cognitive and functional decline and beyond the point where they might qualify for the disease-modifying therapies, where early AD is the sort of defining boundary. So, I think more awareness and more screening in primary care settings, perhaps more community outreach to let people know that changes in memory that affect daily function are not normal as part of the aging process and should be evaluated for intervention. So, there's lots of places in our healthcare community where we could foster better outreach, better knowledge to get more folks access to the medicines. And this is before we even get to cost. Dr Monteith: Yeah, yeah. And obviously, there's some stigma as well.  Dr Geldmacher: That's right.  Dr Monteith: Really recognizing what the issues are and diving and asking those questions and funding research that asks those questions, as you mentioned, is really important. And then you have also a nice area where, you know, looking on the impact of treatments on caregiver-related outcomes, and of course ultimately want to keep patients out of nursing homes and prevent death. And so, can you talk a little bit about that? And, you know, mainly the caregiver burden.  Dr Geldmacher: So, my research in that area goes back a long way now. But I learned early in the course of therapy that many times the outcome that the family is noticing for symptomatic therapies is not a change in the patient's memory per se, but that there is less work involved in the caregiving. Less time is spent in direct caregiving roles. The patient may shadow less and because they have better independent cognition. I remember one family member once told me, the medicine you started is a godsend because now I can go to the bathroom by myself and he's not pounding on the door saying where are you, where are you. He's able to recall long enough that I'm in the bathroom that I have that moment of privacy. That was very meaningful to me to hear that. So. Dr Monteith: Cool. So why don't you just help us wrap this up and just give us, like, three main takeaway points that we should be getting out of your article? Dr Geldmacher: The three points that I would emphasize from my article is that the symptomatic therapies provide meaningful benefits and measurable, consistent, meaningful benefits. The second is that those benefits extend beyond things like cognitive test scores and into things like caregiver well-being and maintenance of independence in the home environment. And the third is that the disease-modifying therapies are an exciting opportunity to modify the pathology, but we still are learning about their cost effectiveness and their long-term benefit both to individuals and to society. But the only way we're going to learn that is by using them. And that was the experience that we gained from the symptomatic therapies that took use in the community for years before we really began to understand their true value. Dr Monteith: Thank you. That was excellent. And I put you on the spot, too.  Dr Geldmacher: No problem.  Dr Monteith: Again, today I've been interviewing Dr David Geldmacher, whose article on treatment of Alzheimer's disease appears in the most recent issue of Continuum on Dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at contentpub.com/AudioCME. Thank you for listening to Continuum Audio.

Aprueban registro sanitario de lecanemab medicamento contra el AlzheimerEvo Morales será el candidato del partido Movimiento al Socialismo para 2025Más información en nuestro Podcast

Der Wirkstoff Lecanemab, der den Gedächtnisverlust bei Alzheimer verlangsamen soll, steht in der EU kurz vor der Zulassung. Aber es gibt Zweifel, ob die Herstellerfirma bei der Zulassungsstudie für das Medikament ethisch einwandfrei gehandelt hat. Kohlenbach, Lukas www.deutschlandfunk.de, Forschung aktuell

El doctor Jesús Porta-Etessam explica en La Brújula los avances de este medicamento. 

Etwa eine Million Menschen leiden in Deutschland an Alzheimer. Eine Therapie mit dem Antikörper Lecanemab könnte den Krankheitsverlauf verlangsamen. Die Europäische Arzneimittelagentur spricht sich jetzt für eine Zulassung aus. Was kann das Medikament bewirken? Stefan Troendle im Gespräch mit David Beck, SWR-Wissenschaft

The first drugs to slow Alzheimer's progression have been making headlines around the world. For researchers in the field, the arrival of these two therapies called Lecanemab and Donanemab is testament to decades of advancements in the field of Alzheimer's research because for the first time they go further than modifying the symptoms and have been shown in trials to slow down cognitive decline. For patients and families these treatments offer hope that the amount of quality time they'll have together could be lengthened. Around the world regulatory bodies are weighing up their effectiveness, safety and cost. In the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lecanemab and Donanemab for use but the National Institute for Health and Care Excellence (NICE) rejected them for use in the NHS on the basis the benefit to patients did not outweight the cost, although they could still be available privately.Presenter James Gallagher examines the decision with Professor of Public Health Carol Brayne from the University of Cambridge and neuroscientist Professor Tara Spires-Jones from the University of Edinburgh. Then, looking forward, he meets scientists searching for future treatments including Dr Emma Mead, chief scientist at the Alzheimer's UK Drug Discovery Institute at the University of Oxford, Dr Ashvini Keshavan, co-lead of University College London's ADAPT blood biomarker trial, Selina Wray, Professor of Molecular Neuroscience and Alzheimer's Research UK Senior Research Fellow at University College London, and UK Dementia Research Institute Emerging Leader Dr Claire Durrant.This programme was produced in partnership with The Open University.Presenter: James Gallagher Producer: Tom Bonnett Editor: Holly Squire

Where is Singapore dementia research headed? Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. This episode is on a topic that affects millions worldwide: dementia. We will explore the differences between how dementia presents in Asian versus Caucasian populations, and what this means when it comes to early intervention and future treatments.  Professor Nagaendran Kandiah, director of the Dementia Research Centre (Singapore) at the Lee Kong Chian School of Medicine at Nanyang Technological University is our guest. He also talks to Joyce Teo about Lecanemab and Donanemab, two drugs that can slow down Alzheimer's disease by treating the root cause. Donanemab, for instance, has been approved, but not recommended for the National Health Service in England. Highlights (click/tap above) 1:05 Differences in the way dementia shows up in Asians and Caucasians 6:01 A blood test to pick up dementia 11:59 Lecanemab and Donanemab, two drugs that have been approved elsewhere for those with Alzheimer's disease 18:50 What can you do to lower your risk of vascular dementia? Check out ST's new series, No health without mental health: https://str.sg/mentalhealthmatters Read Joyce Teo's stories: https://str.sg/JbxN Host: Joyce Teo (joyceteo@sph.com.sg) Produced and edited by: Amirul Karim Executive producers: Ernest Luis and Lynda Hong Follow Health Check Podcast here and get notified for new episode drops: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 ST Podcast website: http://str.sg/stpodcasts ST Podcasts YouTube: https://str.sg/4Vwsa --- Get The Straits Times' app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX #healthcheckSee omnystudio.com/listener for privacy information.

Where is Singapore dementia research headed? Synopsis: Every first Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. This episode is on a topic that affects millions worldwide: dementia. We will explore the differences between how dementia presents in Asian versus Caucasian populations, and what this means when it comes to early intervention and future treatments.  Professor Nagaendran Kandiah, director of the Dementia Research Centre (Singapore) at the Lee Kong Chian School of Medicine at Nanyang Technological University is our guest. He also talks to Joyce Teo about Lecanemab and Donanemab, two drugs that can slow down Alzheimer's disease by treating the root cause. Donanemab, for instance, has been approved, but not recommended for the National Health Service in England. Highlights (click/tap above) 1:05 Differences in the way dementia shows up in Asians and Caucasians 6:01 A blood test to pick up dementia 11:59 Lecanemab and Donanemab, two drugs that have been approved elsewhere for those with Alzheimer's disease 18:50 What can you do to lower your risk of vascular dementia? Check out ST's new series, No health without mental health: https://str.sg/mentalhealthmatters Read Joyce Teo's stories: https://str.sg/JbxN Host: Joyce Teo (joyceteo@sph.com.sg) Produced and edited by: Amirul Karim Executive producers: Ernest Luis and Lynda Hong Follow Health Check Podcast here and get notified for new episode drops: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Feedback to: podcast@sph.com.sg --- Follow more ST podcast channels: All-in-one ST Podcasts channel: https://str.sg/wvz7 ST Podcast website: http://str.sg/stpodcasts ST Podcasts YouTube: https://str.sg/4Vwsa --- Get The Straits Times' app, which has a dedicated podcast player section: The App Store: https://str.sg/icyB Google Play: https://str.sg/icyX #healthcheckSee omnystudio.com/listener for privacy information.

Kohlenbach, Lukas www.deutschlandfunk.de, Forschung aktuell

On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer's research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on:The impact of molecular diagnostics on Alzheimer's researchRecent Alzheimer's drug approvalsThe future of Alzheimer's research*Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital*Chapters00:00 – Introduction01:54 – Why Sarah began studying Alzheimer's03:39 – Current tools and needs for future Alzheimer's diagnostics09:52 – Recent drug approvals in the Alzheimer's space and their relationship to diagnostics14:26 – Is it possible to develop biomarkers that detect Alzheimer's at its earliest stages?16:36 – What is limiting the development of new Alzheimer's biomarkers?17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer's19:33 – The genetics of Alzheimer's22:19 – Novel approaches to identifying and understanding Alzheimer's pathology 25:54 – Where can proteomics advance Alzheimer's research?31:25 – The role of proteomics in Alzheimer's animal models34:33 – Sarah's hopes for the next 10 years of Alzheimer's research41:39 - OutroResourcesDominant Inherited Alzheimer's Network (DIAN) trials research updateso In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer's disease.Amyloid plaque reducing clinical trials:o Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022)o Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023)o Lecanemab in Early Alzheimer's Disease (Van Duck et al. 2022)Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024)o Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer's diseaseResurrecting the Mysteries of Big Tau (Fischer and Baas 2021)o Review covering a potentially neuro-protective form of tau called “Big tau”Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease (Hurst et al. 2023)o Paper linking the NRN1 protein to cognitive resilience in...

호주의 의약품관리청이 치매 신약 레캐나맙(Lecanemab)의 승인을 거부했습니다. 이 신약의 스폰서 회사는 이번 결정에 항소할 계획이라고 밝혔습니다.

Развојот на првиот лек по 30 години што ја модифицира болеста - а не само симптомите - на најчестата форма на деменција, им дава надеж на пациентите. Лекот Lecanemab сега минува низ процес на регулаторно одобрување во Австралија и другите земји во светот, но преголемата цена на лекот значи дека малкумина ќе можат да го набават.

El ministerio comenta las últimas novedades en Open IA (para sorpresa de nadie, ya no es una ONG) y en el Chat GPT (comete errores tontos, y, atención, siempre los cometerá). También se ocupa de los últimos descubrimientos en torno a la gripe aviar en vacas. Resulta que el virus ha mutado para acumularse en las ubres de las vacas y en su leche, y se transmite a través de los sistemas industriales de ordeño, lo que complica muchísimo controlar esta epidemia. Además, contamos el segundo capítulo sobre la historia del Lecanemab, el medicamento contra el Alzhéimer que no se ha aprobado en Europa por su baja efectividad y alto coste (24.000 euros al año para solo un 5% de pacientes con principio de Alzheimer). Pero investigadores europeos reclaman ahora su aprobación porque alertan de que Europa va a la cola en innovación por su exceso de cautela. En esto coinciden con las alarmas que ha sonado Mario Draghi en su informe: 400 páginas que reclaman una inversión anual de 800.000 millones de euros si Europa no quiere perder definitivamente el tren ante China y Estados Unidos. Por ejemplo: el 60% de los elementos que hacen falta para construir un teléfono móvil vienen de China, y esa dependencia es un peligro. Pero la minería de tierras raras es compleja y muy contaminante, de forma que en Europa nadie la quiere cerca. Por cierto, ¿saben lo que es también muy contaminante? Ver vídeos en el móvil. Hacerlo durante 4 horas equivale a un coche que recorra 50km. Volveremos sobre este asunto porque si salimos de casa y nos dejamos la luz encendida 24 horas nos sentimos culpables, pero si mandamos un archivo injusto innecesario, no. Y contaminan lo mismo. 

Los 'Ministros de Ciencia y Tecnología', Nuño Domínguez y Jaime García Cantero, nos traen todos los jueves la actualidad que avanza a pasos agigantados, mucho más rápido de lo que tardamos en aprendernos el nombre del medicamento contra el Alzheimer, Lecanemab que es uno de los temas ministeriales que pondrán sobre la mesa, además de cuánto contamina Internet. La nueva incorporación al club de 'Amigas Alegres' es la cantante Rosa León. Hoy en la clase de 'Lenguaje', nuestra profesora Lola Pons ha aprovechado que estamos en el Día Europeo de las Lenguas para explicarnos unas nociones básicas de multilingüismo. Nuestro crítico de 'Vida y cine', Javier Ocaña, nos trae las novedades de la cartelera, "La reina roja" y "Nevenka" y además, su crítica bajo demanda, pedida por nuestros oyentes, a la "La Gran Belleza". Con Ainhoa Aguirregoitia dejamos el programa 'Al Dente' hablando del cangrejo real.

Dr. Edward G. Shaw, MD, MA, is dually trained as a physician and mental health counselor. He was the primary care partner for his late wife Rebecca, who was diagnosed with early-onset Alzheimer's disease in 2007 at age 53 and died in 2016 after a 9-year journey. Ed was a practicing academic radiation oncologist for 23 years, specializing in the treatment of adults and children with brain cancer. In 2010, inspired by Rebecca's journey, his medical interest shifted to dementia diagnosis and treatment, and with his additional training in mental health counseling, he founded the Memory Counseling Program in 2011, part of the Section on Gerontology and Geriatric Medicine and the Sticht Center on Healthy Aging and Alzheimer's Prevention at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina. The Program serves individuals, couples, and families affected by Alzheimer's disease or another type of dementia. Dr. Shaw has also authored four books on Dementia which we will discuss shortly.https://www.seniorcareauthority.com/resources/boomers-today/

In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer's disease. Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.Today's guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer's therapies, as growing biological understanding of Alzheimer's risk and resilience bear fruit with promising new approaches to treatment.Learn More:Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.Amyloid Drug Skepticism:Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies(Commentary, Journal of Alzheimer's Disease, 2024)New Drug Approved for Early Alzheimer's (New York Times, 2024)Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)One step back: Why the new Alzheimer's plaque-attack drugs don't work (Stanford Medicine Scope Blog, 2024)Alzheimer's Genetics Research:Knight-funded research uncovers gene mutations that may prevent Alzheimer's Disease (Knight Initiative for Brain Resilience, 2024)Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)Scientists find genetic Alzheimer's risk factor tied to African ancestry (Stanford Medicine, 2023)Episode CreditsThis episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. A global large-scale trial testing the use of Lecanemab provided the first evidence of a treatment to slow down the progression of Alzheimer's. - Perkembangan obat pertama dalam 30 tahun yang mengubah penyakit – dan bukan hanya gejala - bentuk paling umum dari demensia telah memberikan harapan kepada pasien. Uji coba skala besar global yang menguji penggunaan Lecanemab, memberikan bukti pertama pengobatan untuk memperlambat perkembangan Alzheimer.

The development of the first drug in 30 years that modifies the disease - and just the symptoms - of the most common form of dementia has given hope to patients. - Pengembangan obat pertama dalam 30 tahun yang memodifikasi penyakit dan hanya gejalanya dari bentuk demensia yang paling umum telah memberikan harapan bagi pasien.

30 yıl sonra hastalığı ve sadece semptomları değiştiren ilk ilacın geliştirilmesi, en yaygın demans formunun hastalarina umut verdi. Lecanemab adlı bu yeni ilacın kullanımını test eden küresel bir büyük ölçekli deneme, Alzheimer'ın ilerlemesini yavaşlatmak için bir tedavinin ilk kanıtını sağladı. Lecanemab ilacı şu anda Avustralya ve dünyadaki diğer ülkelerde bir onay sürecinden geçiyor, ancak fahiş maliyeti nedeniyle bu ilaca çok az kişi buna erişebilecek.

The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it. - 最も一般的な認知症、アルツハイマー病の進行を遅らせる新薬「レカネマブ」がイギリスで承認されました。この薬は現在、オーストラリアや世界各国で承認手続きが行われています。しかし多くの人は、レカネマブの使用に莫大なコストがかかることを案じています。

Lần đầu tiên trong 30 năm, y học đã nghiên cứu ra một loại thuốc Lecanemab cho căn bệnh mất trí nhớ, với các thử nghiệm toàn cầu cung cấp bằng chứng về khả năng làm chậm sự tiến triển của bệnh Alzheimer chứ không chỉ giảm triệu chứng, đã mang lại hy vọng cho những bệnh nhân dementia dạng phổ biến nhất của căn bệnh này. Loại thuốc này hiện đang trong quá trình phê duyệt tại Úc và nhiều quốc gia khác, nhưng giá thành quá cao có thể khiến nhiều người không tiếp cận được.

Dr Chris Smith and the Naked Scientist team present the latest science news, analysis and breakthroughs.This week: The regulator says the Alzheimer's drug Lecanemab is safe, but NICE say we can't afford it. The UK Ministry Of Defence launches its first Earth imaging satellite. And the BBC's Frank Gardner on why the UK's butterflies need our help.Plus is there a link between some cosmetics and cosmetic trends and cancer? We examine this in more detail in the second part of the programme.

In this edition of The Naked Scientists: the regulator says the Alzheimer's drug lecanemab is safe, but NICE say we can't afford it; also, the UK MOD launches its first Earth-imaging satellite. We talk to the makers; and the BBC's Frank Gardner on why the UK's butterflies need our help... Like this podcast? Please help us by supporting the Naked Scientists

The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Phil Jochelson, therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals, sat down to discuss the phase 4 XYLO study, a randomized controlled study evaluating the effects of switching from high-sodium to low-sodium oxybate on blood pressure in patients with narcolepsy. Jochelson gave some insight regarding the conduct of the trial, including end points, objectives, and patient demographics, as well as some of the benefits to studying blood pressure and cardiovascular risks. In addition, he discussed enhancements to narcolepsy care through low-sodium oxybate, the importance of unique studies like XYLO, and the need to educate clinicians on sodium load and its risks.  Looking for more sleep disorders discussion? Check out the NeurologyLive® sleep disorders clinical focus page. Episode Breakdown: 1:15 – Reasons behind the XYLO study and links between high sodium intake and cardiovascular risk 4:45 – Patient demographics; inclusion and exclusion criterias 6:40 – Neurology News Minute 9:25 – Overview of XYLO and determining what a successful study looks like 15:30 – Improved understanding of the benefits of low-sodium oxybate The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EU Regulatory Review Adopts Negative Opinion of Lecanemab as Treatment for Alzheimer Disease GLP-1 Agonist Liraglutide Shows Protective Effects on Alzheimer Disease in Phase 2 Trial FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Lecanemab wäre die erste ursächlich wirkende Alzheimer-Therapie in Europa gewesen. Doch die Behörde EMA hat sich gegen eine Zulassung ausgesprochen. Eine enttäuschende Entscheidung, denn das Medikament sei wirksam, sagt Neurologe Klaus Fließbach. Fecke, Britta www.deutschlandfunk.de, Forschung aktuell

This time on Ask!, Dr Chris explains how tree rings helped scientists confirm last summer was the hottest for 2000 years. Also, how were the pyramids built? And where are we with understanding and treating Alzheimer's disease? Like this podcast? Please help us by supporting the Naked Scientists

This time on Ask!, Dr Chris explains how tree rings helped scientists confirm last summer was the hottest for 2000 years. Also, how were the pyramids built? And where are we with understanding and treating Alzheimer's disease? Like this podcast? Please help us by supporting the Naked Scientists

To mark Dementia Acton Week, Tony is bringing you a special episode dedicated to the past, present and future of this difficult disease with his expert guest Fiona Carragher, Director of Research and Influencing at the Alzheimer's Society. Dementia the UK's number one killer, 1 in 3 people will develop dementia in their lifetime and yet most of us don't know a great deal about it. But this is a defining year in the history of Alzheimer's with two new drugs: Lecanemab and Donanemab which have been found, for the first time ever, to slow the progression of the disease. Hosted by Sir Tony RobinsonWithFiona Carragher, Director of Research and Influencing at the Alzheimer's Society. X @alzheimersoc | FB @alzheimers society | IG @alzheimerssocIf you're worried about yourself, or someone close to you, then check your symptoms today using Alzheimer's Society's symptom checklist. Visit alzheimers.org.uk/checklist or call the Dementia Support Line on 0333 150 3456Follow: X @cunningcastpod Instagram @cunningcastpod YouTube @Cunningcast Credits: Series Producer: Melissa FitzGerald X @melissafitzg Executive Producer: Dominic de Terville Cover Art: The Brightside A Zinc Media Group production If you enjoyed my podcast, please leave us a rating or review. Thank you, Love Tony x Hosted on Acast. See acast.com/privacy for more information.

Dr. Andrew Budson is Chief of Cognitive Behavioral Neurology at the VA Boston Healthcare System, Associate Director of the Boston University Alzheimer's Disease Research Center, Professor of Neurology at Boston University, and Lecturer in Neurology at Harvard Medical School. He has written 9 books, including Six Steps to Managing Alzheimer's Disease and Dementia, Why We Forget and How to Remember Better, and his latest, Seven Steps to Managing Your Aging Memory—now in its 2nd edition—which explains how to distinguish changes in memory due to Alzheimer's versus normal aging, what medications, diets, and exercise regimes can help, and the best habits, strategies, and memory aids to keep your memory strong.Sponsor: www.SeniorCareAuthority.com

Dr. Jason Crowell talks with Dr. Anelyssa D' Abreu about her recently posted NeuroByte on key features in Lecanemab.  Watch the NeuroByte now! 

The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment. Related Podcast Links: Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241 Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414 Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333 Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052 Related Article Links: Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1 Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study:  https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770 Disclosures can be found at Neurology.org